Background
Atray was co-founder and CEO of Coral Genomics a company that focused creating diagnostic tests to predict individual patient drug (and drug combination) response. After being acquihired by Gordian Bio, he served as VP of Technology building in vivo perturbation screens in complex disease models including ungulates, monkeys, and more (side-by-side with Wyatt).
Atray has created genomics screening technologies including Perturb-seq (used throughout pharma and by many drug discovery startups incl. Xaira, insitro, Celsius, NewLimit, and Gordian) and Shuffle-seq
Education
Atray earned his PhD from MIT working at the Broad Institute under the mentorship of Aviv Regev. He was inspired to pursue life sciences after his B.S.E. in Mechanical and Aerospace Engineering from Princeton as engineering tools like CRISPR and single cell sequencing finally allowed researchers to perturb and measure biology at scale.
My role
In addition to his role as CEO, Atray leads our Data team's efforts to analyze public and proprietary data towards prioritizing drug combinations.
Background
Wyatt developed a combinatorial CRISPR screening platform at Weill Cornell in high school to study blood cancers. He graduated from Stanford in two years while working at Gordian Biotechnology, where he was the first RA promoted to scientist. At Gordian, Wyatt built and implemented an AAV-CRISPR platform for massive pooled in vivo screens, discovering and correcting sequence motifs responsible for AAV truncation and recombination along the way. Wyatt is now co-founding Oncko with Atray, his former boss at Gordian, and Bill, who they met as an advisor at the start of their journey.
Education
Wyatt did his Biology B.S. (molecular, cellular, and developmental biology) at Stanford. Previously, he attended the Bronx High School of Science.
My role
Wyatt leads the platform team to execute the largest combinatorial and resistance screens ever.
Background
Bill was Senior Vice President and Therapeutic Area Head of Oncology Clinical Development at Gilead Sciences Inc. overseeing the company's Oncology portfolio. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences and Bellicum Pharmaceuticals, and various leadership roles at AbbVie and Genentech/Roche.
Bill developed the newborn screening methodology for detecting primary immunodeficient/SCID newborns now incorporated across all States and multiple countries world-wide.
Education
Bill received his MD and PhD in Immunology from Washington University School of Medicine's Medical Scientist Training Program and completed his medical and post-doctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine.
My role
Bill leads the Translation team's efforts to maximize the translation of our screens to clinically successful drugs including designing and executing our validation experiments.
Background
Andrés has extensive experience in large-scale computational problem-solving and algorithm optimization.
At Coral Genomics, he collaborated on the development of large scale genomics computational algorithms.
He has also worked on recommendation systems, digital fraud detection, and large-scale data mining processes.
Andrés implemented DNARecords, an extensible sparse format for petabyte-scale genomics analysis, tackling computational challenges in large-scale data integration and deep learning model compatibility.
Education
Andrés completed an MSc in Artificial Intelligence after several years working alongside data scientists, drawn by their expertise. His academic background includes a BSc in Mathematics from the University of Almería, but it is the blend of mathematics, machine learning, and large-scale data that fuels his professional growth.
My role
Andrés orchestrates Oncko's data pipelines, machine learning, and IT solutions.
Background
Madinah was a research associate at Aperture Therapeutics, developing in vitro functional and biochemical screens evaluating candidate oligonucleotide therapies for neurodegenerative diseases. She previously held roles at leading biopharma companies, including Singular Genomics, Becton Dickinson, and Takeda Pharmaceuticals.
Madinah produced majority of the data used to advance two novel oligonucleotide therapeutic programs into preclinical rodent studies.
Education
Madinah has a B.S. in Pharmacological Chemistry from University of California, San Diego.
My role
Madinah focuses on optimizing and executing pooled, combinatorial, perturbation screens as part of target identification and validation efforts.
The Palmer Laboratory investigates combinations of cancer therapies: understanding the mechanisms of successful drug combinations, to inform the development of combinations with new cancer therapies. Our approach is a synthesis of experimental studies, computational analysis of clinical data, and mathematical modeling.
The Gilbert Laboratory Website
The Gilbert laboratory's expertise is in synthetic biology, functional genomics and cancer biology. We are interested in new ways to model and overcome drug resistance in prostate cancer, hematopoietic malignancies and lung cancer. We use genome scale screens, genetic interaction mapping and genome engineering to model and map the genetic and epigenetic causes underlying why some patients are cured and others are not by cancer therapy. We are also building new CRISPR tools to edit the epigenome which will allow us to manipulate gene expression in new ways.
Alice Shaw is chair of the Department of Medical Oncology and chief of strategic partnerships at Dana-Farber Cancer Institute. As department chair, she leads a world-renowned department of over 300 faculty members who are performing groundbreaking fundamental, translational and clinical research, while also providing exceptional clinical care. In her role as chief of strategic partnerships, she oversees the collaborative efforts between researchers and the life sciences industry to help accelerate the development of innovative new therapies for patients with cancer. Dr. Shaw was previously vice president and global head of translational clinical oncology at Novartis for almost five years. Prior to Novartis, Dr. Shaw was the director of the Center for Thoracic Cancers at Massachusetts General Hospital (MGH), the Paula O’Keeffe endowed chair of Thoracic Oncology at MGH, co-leader of the Dana-Farber/Harvard Cancer Center Thoracic Oncology Program, and professor of medicine at Harvard Medical School. Since 2008, Dr. Shaw has studied resistance to targeted therapies in the lab and the clinic, and helped develop numerous targeted therapies for patients with oncogene-driven lung cancers. Since her return to academia, Dr. Shaw has continued her research in oncogene-driven lung cancers, and is co-leading the DFCI Center for RAS Therapeutics.